Genetic modifiers of APOE-ε4-associated cognitive decline
Alex G Contreras1,2, Skylar Walters1, Jaclyn M Eissman1,2
1Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Nature Communications
|February 20, 2026
Summary
Researchers identified new genes influencing cognitive decline in individuals with the APOE-ε4 allele, a major Alzheimer's risk factor. These genetic discoveries offer potential targets for interventions to preserve brain health, especially in diverse populations.
Area of Science:
- Neurogenetics
- Alzheimer's Disease Research
- Cognitive Aging
Background:
- The Apolipoprotein E ε4 (APOE-ε4) allele is the primary genetic risk factor for late-onset Alzheimer's disease.
- APOE-ε4's influence is not absolute, necessitating the identification of modifying genetic and environmental factors.
- APOE-ε4 is associated with accelerated cognitive decline, underscoring the need to find genetic modifiers.
Purpose of the Study:
- To investigate genetic factors that modify APOE-ε4-associated cognitive decline.
- To conduct cross-ancestry, APOE-ε4-stratified genome-wide association studies (GWAS).
- To analyze harmonized cognitive data from diverse participants.
Main Methods:
- Utilized harmonized cognitive data from 32,778 participants (29,354 non-Hispanic White, 3,424 non-Hispanic Black).
- Employed APOE-ε4-stratified and interaction GWAS.
- Assessed late-life cognition using composite scores for memory, executive function, and language.
Main Results:
- Identified two genome-wide significant loci in APOE-ε4 carriers associated with executive function, with broader cognitive effects.
- Discovered a genome-wide significant association at ITGB8 for executive function in non-carriers, and another locus for language.
- Linked identified loci to SEMA6D, GRIN3A, and ITGB8 via expression and methylation databases; implicated SLCO1A2 and DNAH11.
- Found differences in genetic correlations for immune-related traits by APOE-ε4 status, suggesting immune predispositions may worsen cognitive risk in carriers.
Conclusions:
- New genetic loci modifying cognitive decline in APOE-ε4 carriers and non-carriers have been identified.
- Findings suggest that immune-related predispositions may exacerbate cognitive risk in APOE-ε4 carriers.
- The study highlights the importance of diverse ancestry in genetic studies of cognition and Alzheimer's disease.
More Related Videos
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
8.8K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
28.2K
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
30
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
01:28Human Genetics
1.7K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.7K
01:29Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
24
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
01:26Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
696
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
696